Paul Tudor Jones’s Teva Pharmaceuticals TEVA Stock Holding History

Paul Tudor Jones’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72M	Sell	80,300 -153,200	-66%	-$5.1M	﹤0.01%	1731
2026 Q1	$7.03M	Sell	233,500 -90,400	-28%	-$2.91M	0.01%	955
2025 Q4	$10.1M	Buy	323,900 +289,500	+842%	+$7.13M	0.02%	739
2025 Q3	$695K	Sell	34,400 -24,400	-41%	-$429K	﹤0.01%	2507
2025 Q2	$985K	Sell	58,800 -20,300	-26%	-$328K	﹤0.01%	2137
2025 Q1	$1.22M	Buy	+79,100	New	+$1.41M	﹤0.01%	1688
2024 Q4	–	Sell	-67,600	Closed	-$1.22M	–	3504
2024 Q3	$1.22M	Buy	67,600 +53,800	+390%	+$942K	﹤0.01%	1505
2024 Q2	$224K	Buy	+13,800	New	+$213K	﹤0.01%	2120
2023 Q2	–	Sell	-200,000	Closed	-$1.77M	–	2918
2023 Q1	$1.77M	Buy	+200,000	New	+$1.98M	0.03%	854

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Paul Tudor Jones's TEVA Position: Q2 2026 in Review

Paul Tudor Jones reduced its Teva Pharmaceuticals (TEVA) stake by 10% in Q2 2026, selling an estimated $1.82M and leaving 490,000 shares worth $16.6M. The position accounts for 0.02% of the portfolio, ranked #572.

Paul Tudor Jones first reported a position in TEVA in Q1 2014 and has held it in 28 quarters since. The position peaked at $34.3M in Q1 2015. 671 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Paul Tudor Jones held 490,000 shares of Teva Pharmaceuticals worth $16.6M as of Q2 2026.
Paul Tudor Jones sold 54,501 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.82M.
Teva Pharmaceuticals made up 0.02% of Paul Tudor Jones's portfolio in Q2 2026, its #572 holding.
Paul Tudor Jones first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 28 quarters since.
Paul Tudor Jones's Teva Pharmaceuticals position peaked at $34.3M in Q1 2015.
671 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.